Breaking News, Financial News

Financial Report: Genzyme 4Q

Fabrazyme sales were $126 million in the quarter (+10%) and $494 million for the year (+17%). Sales of Cerezyme were $305 million in the quarter (+2%) and for the year were $1.2 billion (+9%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genzyme 4Q Revenues: $1.2 billion (+13%) 4Q Earnings: $86.7 million (+10%) FY Revenues: $4.6 billion (+21%) FY Earnings: $421.1 million (-12%) Comments: Fabrazyme sales were $126 million in the quarter (+10%) and $494 million for the year (+17%). Sales of Cerezyme were $305 million in the quarter (+2%) and for the year were $1.2 billion (+9%). Aldurazyme sales were $38 million in the quarter (+9%) and $152 million for the year (+23%). Revenue from the Cardiometabolic and Renal seg...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters